newsfilter
← Latest News
GlobeNewswire·

SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference

  • SCYNEXIS, Inc. (NASDAQ: SCYX) senior leadership will participate in the 3rd Annual Guggenheim Healthcare Innovation Conference in Boston on November 9-11, 2026.
  • One-on-one meetings are scheduled for November 9-10, 2026.
  • A fireside chat is set for Monday, November 9, 2026, from 2:30 p.m. to 3:00 p.m. ET.
  • A live webcast of the fireside chat will be available, with a replay accessible on the company website for 90 days post-event.
  • SCYNEXIS is developing SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), which holds Orphan Drug designation.
  • The company's proprietary "fungerps" platform includes BREXAFEMME® (ibrexafungerp tablets), licensed to GSK, \& SCY-247, which is in clinical development for invasive fungal diseases.
  • Investor relations inquiries can be directed to John Fraunces at LifeSci Advisors via phone or email.